



FOR IMMEDIATE RELEASE

## **Hypha Discovery announces “One-Stop Metabolite Shop” solution to support pharmaceutical and agrochemical R&D**

Slough, UK – 3<sup>rd</sup> December 2019: [Hypha Discovery Limited](#), a leading specialist CRO, has launched their “One-Stop Metabolite Shop” to provide a complete solution for provision of small molecule drug metabolites to pharmaceutical and agrochemical companies worldwide.

Over the last eight years, Hypha has developed a microbial and mammalian biotransformation platform, with a proven reputation for biotransforming drugs and agrochemicals into metabolites and environmental fate derivatives that couldn’t be made using conventional synthetic methods. The service that Hypha provides is now regarded, globally, as second to none.

Today, Hypha announces that it has added to its existing portfolio of services, the capability to chemically synthesise glucuronide metabolites using highly effective proprietary methods that modify the parent compound. Thus Hypha can now offer clients a combination of both biological and chemical techniques, i.e. a one-stop offering for all metabolite exploration needs, meaning that clients can quickly establish a method to identify and scale up any type of metabolite.

Pivotal to Hypha's portfolio is the PolyCYPs<sup>®</sup> product. Launched earlier this year and based on Hypha patented technology, PolyCYPs kits provide clients with simple-to-use enzyme catalysts to access cytochrome P450 metabolites in their own laboratories. The Company has received hugely positive feedback from its client base with regard to the usability and effectiveness of PolyCYPs. Hypha has further developed this technology and is today announcing the launch of the enhanced product, PolyCYPs+, which incorporates new enzymes with extra capabilities, including the ability to access metabolites produced via other metabolic pathways.

Liam Evans, CEO of Hypha Discovery, commented: *“Our clients commend us for our determination to solve even the most complex metabolite challenges. This reputation for technical excellence and quality customer service is important to us, and as such we have continued to invest in developing innovative research to provide our clients with the most comprehensive metabolite solutions available anywhere”*.

To learn more, visit [Hypha's one-stop-shop metabolite solutions](#).

## Ends

For further information, contact:

### Corporate Contact:

Julia Shanu-Wilson, Head of Scientific Communications

T: +44 (0)1753 568300

E: [julia.shanuwilson@hyphadiscovery.co.uk](mailto:julia.shanuwilson@hyphadiscovery.co.uk)

### PR Contact:

Juliette Craggs

Sciad Communications Ltd

T: +44 (0)20 7470 8801

E: [HyphaDiscovery@sciad.com](mailto:HyphaDiscovery@sciad.com)

[Notes to Editors](#)

## About Hypha Discovery Limited

Hypha Discovery Ltd is a UK-based CRO providing solutions to pharmaceutical and agrochemical R&D partners through the production of mammalian and microbial metabolites, as well as specialising in microbially-derived chemicals. We have delivered metabolite projects for over 120 companies, including 7 of the top 10 pharma companies and 4 out of 5 of the top agrochemical companies.

PolyCYPs® was developed in collaboration with Professor John Ward of UCL, with financial support from Innovate UK.